AU3073700A - Troglitazone-containing medicinal compositions for inhibiting apoptosis - Google Patents

Troglitazone-containing medicinal compositions for inhibiting apoptosis

Info

Publication number
AU3073700A
AU3073700A AU30737/00A AU3073700A AU3073700A AU 3073700 A AU3073700 A AU 3073700A AU 30737/00 A AU30737/00 A AU 30737/00A AU 3073700 A AU3073700 A AU 3073700A AU 3073700 A AU3073700 A AU 3073700A
Authority
AU
Australia
Prior art keywords
troglitazone
medicinal compositions
inhibiting apoptosis
containing medicinal
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30737/00A
Inventor
Shigeko Deguchi
Jun Harada
Isao Kaneko
Tomiichiro Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of AU3073700A publication Critical patent/AU3073700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU30737/00A 1999-01-19 2000-01-19 Troglitazone-containing medicinal compositions for inhibiting apoptosis Abandoned AU3073700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1035499 1999-01-19
JP11/10354 1999-01-19
PCT/JP2000/000226 WO2000043007A1 (en) 1999-01-19 2000-01-19 Troglitazone-containing medicinal compositions for inhibiting apoptosis

Publications (1)

Publication Number Publication Date
AU3073700A true AU3073700A (en) 2000-08-07

Family

ID=11747855

Family Applications (2)

Application Number Title Priority Date Filing Date
AU30736/00A Abandoned AU3073600A (en) 1999-01-19 2000-01-19 Inhibitor for nerve cell death due to glutamic acid cytotoxicity
AU30737/00A Abandoned AU3073700A (en) 1999-01-19 2000-01-19 Troglitazone-containing medicinal compositions for inhibiting apoptosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU30736/00A Abandoned AU3073600A (en) 1999-01-19 2000-01-19 Inhibitor for nerve cell death due to glutamic acid cytotoxicity

Country Status (2)

Country Link
AU (2) AU3073600A (en)
WO (2) WO2000043007A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002488A1 (en) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agent for brain hemorrhage
CN112521382A (en) * 2020-12-14 2021-03-19 西南大学 Aloe-emodin thiazolidinedione compound and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS62234085A (en) * 1985-12-18 1987-10-14 Sankyo Co Ltd Remedy for diabetic complication comprising thiazolidine derivative as active ingredient
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
ATE186724T1 (en) * 1987-09-04 1999-12-15 Beecham Group Plc SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05202042A (en) * 1992-01-24 1993-08-10 Sankyo Co Ltd Therapeutic agent for diabetic complication
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimidazole derivatives and pharmaceutical compositions containing the same
KR19990087076A (en) * 1996-04-05 1999-12-15 다께다 구니오 A pharmaceutical combination containing angiotensin II and a compound having antagonistic activity
JP2000511883A (en) * 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ Modulators of molecules with phosphotyrosine recognition units
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
IL128771A0 (en) * 1996-09-12 2000-01-31 Sankyo Co An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof
DE69838789T2 (en) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
ID26986A (en) * 1998-07-21 2001-02-22 Smithkline Beecham P L C Cs USE OF IMPROVING GLUCOSE TO REDUCE APOPTOSIS

Also Published As

Publication number Publication date
WO2000043006A1 (en) 2000-07-27
WO2000043007A1 (en) 2000-07-27
AU3073600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
AU3192700A (en) Medicinal compositions
HUP0202513A2 (en) Betha-carboline pharmaceutical compositions
AU1071301A (en) Pharmaceutical compounds
AU781269C (en) Pharmaceutical compositions
AU5271300A (en) Radiopaque compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
IL148864A0 (en) Pharmaceutical compositions containing nimesulide
AU3556400A (en) Pharmaceutical compositions
AU2005300A (en) Medicinal compositions
GB9923436D0 (en) Pharmaceutical compositions
AU1887401A (en) Medicinal composition
GB9904163D0 (en) Pharmaceutical compositions
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU5460800A (en) Pharmaceutical transdermal compositions
AU6460400A (en) Pharmaceutical compositions
AU3997700A (en) Anti-first-pass effect compounds
AU2001273919A1 (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
AU2681500A (en) Rapidly-soluble compositions
AU1732401A (en) Medicinal compositions for oral use
AU6460200A (en) Pharmaceutical compositions
AU5722900A (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase